What does the evidence say about Phosphatidylcholine Cognitive Performance Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Phosphatidylcholine Cognitive Performance Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Emerging evidence suggests altered circulating metabolite levels in individuals with Alzheimer's disease (AD) and/or mild cognitive impairment (MCI) compared to healthy controls; how these metabolites alter with early cortical amyloidosis-before symptom onset-remains unclear. [Sharmin T (2026); evidence level 4] - Across the spectrum, lower PC-to-LPC ratios were associated with greater cortical amyloid deposition, poorer cognitive performance and higher plasma P-tau181 levels. [Sharmin T (2026); evidence level 4] - Elevated Cer(43:1) levels were also associated with higher cortical amyloid deposition. [Sharmin T (2026); evidence level 4] - This cross-sectional study aimed to investigate plasma metabolites obtained through targeted profiling using the Biocrates AbsoluteIDQ® p400 HR kit. [Sharmin T (2026); evidence level 4] - Background The cognitive-enhancing effects of dietary lecithin are gaining increasing attention, but evidence supporting these claims remains limited. [Li X (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.